Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

NASDAQ:BTX

Eterna Therapeutics Inc.

Last Close

0.20

17/10 04:00

Market Cap

1.05M

Beta: 0.79

Volume Today

2.56M

Avg: 85.42K

PE Ratio

−0.42

PFCF: −0.39

Institutional trades

Institutional Ownership

Current holdings institutionals